Source: http://www.google.com/patents/US5320848?dq=6978253
Timestamp: 2014-09-19 08:10:02
Document Index: 325832512

Matched Legal Cases: ['in fine', 'arts 100', 'arts 100', 'arts 100', 'arts 100', 'arts 100']

Patent US5320848 - Chewable drug-delivery composition - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsA non-aqueous, chewable composition for oral delivery of unpalatable drugs is provided. The composition contains the drug intimately dispersed or dissolved in a pharmaceutically-acceptable lipid that is solid at room temperatures. The composition also has a matrix that contains a granulating agent for...http://www.google.com/patents/US5320848?utm_source=gb-gplus-sharePatent US5320848 - Chewable drug-delivery compositionAdvanced Patent SearchPublication numberUS5320848 APublication typeGrantApplication numberUS 07/889,179Publication dateJun 14, 1994Filing dateMay 27, 1992Priority dateMay 28, 1991Fee statusPaidAlso published asCA2103443A1, CA2103443C, DE69233130D1, DE69233130T2, EP0587744A1, EP0587744A4, EP0587744B1, WO1992021328A1Publication number07889179, 889179, US 5320848 A, US 5320848A, US-A-5320848, US5320848 A, US5320848AInventorsRobert P. Geyer, Vinod V. TulianiOriginal AssigneeAffinity Biotech, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (24), Non-Patent Citations (2), Referenced by (48), Classifications (12), Legal Events (9) External Links: USPTO, USPTO Assignment, EspacenetChewable drug-delivery compositionUS 5320848 AAbstract A non-aqueous, chewable composition for oral delivery of unpalatable drugs is provided. The composition contains the drug intimately dispersed or dissolved in a pharmaceutically-acceptable lipid that is solid at room temperatures. The composition also has a matrix that contains a granulating agent for the total composition and a rapid dispersal agent and optionally additives such as buffering agents, flavoring agents, surfactants, and the like. Methods for the preparation of the chewable compositions are also provided.
What is claimed is: 1. A non-aqueous, chewable composition which disintegrates rapidly in the mouth for oral delivery of unpalatable drugs in which the unpalatable taste of the drug is masked during mastication, comprising:(a) a therapeutically-effective amount of one or more unpalatable drugs intimately dispersed in a solid pharmaceutically-acceptable lipid coating, which lipid is solid at ambient temperature, or mixtures of said lipids, wherein the lipid is present in the composition in an amount of from 5-50 percent by weight. (b) a matrix for said drug and lipid, said matrix consisting essentially of:(i) one or more granulating agents, (ii) a rapid dispersal agent in an amount of from about 2 to about 20 weight percent of the composition, wherein the rapid dispersal agent is blended with the solidified lipid coated drug, and (iii) optionally minor amounts of additives selected from the group consisting of flavoring agents, coloring agents, buffering agents, sweeteners, oils, and surfactants. 2. The composition of claim 1 wherein the rapid dispersal agent comprises at least one agent selected from the group consisting of croscarmellose sodium, sodium starch glycolate, pregelatinized corn starch, and crospovidone.
FIELD OF THE INVENTION This invention relates to a non-aqueous, chewable composition for oral delivery of pharmaceutically-active compounds. More particularly, it relates to lipid-based, chewable formulations for the oral delivery of unpalatable drugs, and processes for preparing the same. The compositions are designed to be chewed and masticated and then swallowed while not only masking the taste of the drug but also providing a pleasant mouth taste and feel.
BACKGROUND OF THE INVENTION Formulations for oral delivery of various pharmaceutically-active compounds, particularly unpalatable ones such as aspirin, ibuprofen, cimetidine, acetaminophen, erythromycin, or the like, are well known in the art. Generally, unacceptable taste characteristics due to acidity, bitterness, burning in the back of the throat, or odorousness, have been overcome, by coatings, capsules, flavoring agents or combinations of these features. See for example, formulations which are intended to be swallowed whole, such as those disclosed in U.S. Pat. No. 4,726,966, which coats granular ibuprofen with an acrylic acid resin in the presence of an organic solvent and water; U.S. Pat. No. 4,835,186, which discloses spray-drying ibuprofen in a suspension of colloidal silica, alcohol, and cellulose acetate; and U.S. Pat. No. 4,916,161, which discloses coating ibuprofen via a wet granulation method using certain methyl cellulose phthalates as taste-masking agents. Each of these formulations, however, has been devised in order to momentarily disguise or prevent these objectionable features while the compound is passing through the mouth and throat and being swallowed without being masticated.
SUMMARY OF THE INVENTION In accordance with the present invention, there is now provided in one aspect, a non-aqueous, chewable composition which disintegrates rapidly in the mouth for the delivery of unpalatable pharmaceutically-active compounds comprising a therapeutically-effective amount of one or more unpalatable pharmaceuticals intimately dispersed or dissolved in a pharmaceutically-acceptable lipid in which each component is solid at ambient temperatures, and a matrix for said drug and lipid comprising (a) one or more solid granulating agents, and, optionally, (b) minor amounts of additives such as buffering agents, sweeteners, flavoring agents, rapid dispersal agents, or the like, or mixtures thereof. "Chewable" products, as used herein, can be in the form of compressed tableted material, or in the form of an uncompressed powder. The chewable composition preferably contains a rapid dispersal agent that is a cellulose derivative, more preferably the dispersal agent is croscarmellose sodium. The chewable composition is formulated to disperse and disintegrate rapidly in the mouth while masking the taste of the drug throughout the mastication process.
DETAILED DESCRIPTION OF THE INVENTION In one embodiment of this invention, the novel compositions may readily be prepared by first heating together, under mildly elevated temperatures of from about 55� to 95� C., the active pharmaceutical ingredient (hereinafter called "drug"), and the lipid, wherein at least the lipid and desirably both components are melted, to form a first melted phase whereby the drug is dispersed or dissolved in the melted lipid. The mixture is then cooled, preferably rapidly by chilling, to about room temperature or below, to provide a solid in which the drug is dispersed or dissolved in a continuous lipid phase. In this way, the drug is in intimate contact with the lipid. It will further be understood that in the case of heat-sensitive drugs, the drug may be added to the lipid after it has cooled down to a point just short of solidification at room temperature. Finally, we have found that the drug and lipid can be mixed vigorously at room temperature, to disperse the drug in the lipid in fine particulate form, i.e. without first melting the lipid and drug. This mixing of the drug and lipid without first melting them can generally be achieved by use of mechanical mixers for 5-10 minutes at temperatures of from about 10�-40� C.
EXAMPLE 1 Four hundred mg lipid (tripalmitin, 90+%, Sigma Chemicals, St. Louis, Mo.) was melted in a vial, using a water bath maintained at around 85.C. To the melted tripalmitin, 400 mg ibuprofen powder was added. Once the drug melted, it was stirred with the melted lipid to produce a homogeneous mixture. Forty mg of sorbitol granulating agent was added to this mixture and mixed into it to produce an even dispersion. The vial was then quickly immersed in an ice bath, while stirring was carried out continuously. In a very short period of time, the mixture was seen to become solid. The material was then powdered. One hundred mg sorbitol powder and 40 mg aspartame powder were added to the final powder mix and stirred into it. The resulting formulation contained ibuprofen at a concentration of about 40% (w/w). The burning sensation associated with the taste of ibuprofen was effectively masked in this preparation. The only taste that could be detected was the sweet taste of the sorbitol and aspartame. This granulated ibuprofen preparation was chewable and contained an adult dose of the drug with no unpleasant taste or sensation.
EXAMPLE 2 Another formulation was prepared in which the internal phase or drug was cimetidine. In this case, 200 mg of cimetidine was stirred into 600 mg tripalmitin at 85� C. The lipid was in a liquid state while the drug was present as a dispersed solid, since the temperature was below its melting point. The drug was stirred into the lipid and 60 mg sorbitol was added. After the cooling and powdering steps, 100 mg of additional sorbitol together with 40 mg aspartame was also added to the mixture. The resulting powdered preparation had a marked decrease in bitter taste compared to the neat drug, and it also had a pleasant, sweet taste.
EXAMPLE 3 In the following formulation, a higher concentration of ibuprofen than normally employed in the final product was incorporated into a preparation of this invention; however, a slight burning sensation was detected. In order to counteract it, some sodium bicarbonate powder was used in the preparation, as buffering agent.
EXAMPLE 4 In the following formulation, the drug/lipid phase was mixed at room temperature without final melting either component. Aspirin, 320 mg, was placed in a vial and 106 mg of hydrogenated vegetable oil (Sterotex NF, Karlshamns Lipid Specialties USA, Columbus, OH) was added to it. This was mixed at room temperature to produce a well-blended mixture. A premix containing 11.5 parts mannitol, 5 parts 100-mesh sorbitol, 1 part corn starch and 2.5 parts Nutrasweet was then prepared separately. Five hundred seventy mg of this premix was added in increments to the lipid/aspirin mixture in increasing amounts. After each addition of premix, the mixture was well blended using hand stirring. The resulting mixture was then compressed into a pill at 2500 psi pressure. The resulting tablet was pleasant and slightly tart tasting.
EXAMPLE 5 Two hundred mg ibuprofen was co-melted with 200 mg hydrogenated vegetable oil, (Sterotex NF) at 85.C. It was well mixed then cooled to solidify the mixture. The resulting solid was ground to a fine powder. To this lipid/drug mixture was added 1 gram of premix containing 11.5 parts mannitol, 5 parts 100 mesh sorbitol, 1 part corn starch and 2.5 parts Nutrasweet. This was added in stepwise increments with stirring after each addition. One μl oil of wintergreen was then added to the mix. The resulting mixture is then compressed into a pill at 10,000 psi pressure. The tablet was pleasant and sweet tasting.
EXAMPLE 6 Seventy-five mg of ranitidine was mixed with 75 mg hydrogenated vegetable oil (Sterotex K) and the lipid melted at about 90.C. The mixture was cooled to room temperature, solidified, and powdered. To this was added 850 mg finely powdered premix containing 11.5 parts mannitol, 5 parts 100 mesh sorbitol, 1 part cornstarch, 2.5 parts Nutrasweet and 2.2 parts Sterotex K lipid. The premix was added, stepwise, with mixing. Twenty-five mg ground citric acid, 8 μl oil of sweet orange, and 25 mg powdered sodium chloride were also added to complete the formulation, which was compressed at 2500 psi to give a pleasantly tart-tasting tablet.
EXAMPLE 7 In the following formulation, the lipid, including chocolate, was first mixed with the matrix prior to addition of the drug.
EXAMPLE 8 One hundred mg erythromycin ethyl succinate was added to 100 mg Sterotex N F that had been melted in a vial and allowed to cool somewhat without solidification. After the drug was added, the mixture was well mixed to produce a solid blend. The mix was then ground to a fine powder. Eight hundred mg premix containing 11.5 parts mannitol, 5 parts 100 mesh sorbitol, 1 part cornstarch and 2.5 parts Nutrasweet was then added in small sequential aliquots and stirred after each addition. The resulting mixture was then compressed at 2500 psi to give a sweet tasting tablet with no bitter taste.
EXAMPLE 9 In order to demonstrate that ibuprofen formulated in the lipid matrix is still available for absorption in the gut, the following study was performed in rats. In a process similar to that used in Example 5, a tablet containing 100 mg ibuprofen was prepared by the hot technique in which the drug and lipid were both co-melted. The final tablet formulation contained 100 mg ibuprofen, 100 mg lipid (Sterotex HM, Karlshamns Lipid Specialties USA, Columbus, OH), and 800 mg matrix which comprised 11.5 parts mannitol, 5 parts 100 mesh sorbitol, 1 part corn starch and 2.5 parts Nutrasweet. A pressure of 5000 psi was used in the tableting process.
EXAMPLE 10 A molten mixture of Sterotex HM (Karlshamns Lipid Specialties USA, Columbus, Ohio 43201) and ibuprofen (Ethyl Corporation, Baton Rouge, La. 70801) in a 2:1 ratio was spray congealed. The product was a powder consisting of spherical particles with a median size of 118 microns.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2887437 *Aug 22, 1956May 19, 1959Pfizer & Co CPalatable vitamin tablet containing an amino acidUS3108046 *Oct 17, 1962Oct 22, 1963Smith Kline French LabMethod of preparing high dosage sustained release tablet and product of this methodUS3279988 *Mar 17, 1965Oct 18, 1966Lilly Co EliProcess of treating helminthiasis with oxadiazole derivativesUS4203997 *Feb 16, 1978May 20, 1980Merck Patent Gesellschaft Mit Beschrankter HaftungDirectly-pressable ascorbic acid-containing granulatesUS4206209 *Nov 2, 1978Jun 3, 1980Kracauer PaulSublingual aspirin tabletUS4375468 *Apr 8, 1982Mar 1, 1983Verex Laboratories, Inc.Constant order release aspirin composition and method of treating arthritisUS4517179 *Mar 6, 1984May 14, 1985Pennwalt CorporationRapid dissolving, uniform drug compositions and their preparationUS4695467 *Jul 5, 1985Sep 22, 1987Fujisawa Pharmaceutical Co., Ltd.Starch derivatives, water soluble polymerUS4726966 *Nov 25, 1986Feb 23, 1988Showa Shinyaku Co., Ltd.Preparation of coated granular ibuprofen microsphereUS4755387 *Mar 21, 1985Jul 5, 1988The Procter & Gamble CompanyTherapeutic particlesUS4761407 *Oct 22, 1985Aug 2, 1988Rhone-Poulenc SanteKetoprofen, prednisone or prednisolone in solid excipientUS4831058 *Sep 30, 1987May 16, 1989Boots Company PlcTherapeutic agentsUS4835186 *Jun 15, 1987May 30, 1989American Home Products CorporationSilica, cellulose acetate phthalate, alkanolUS4835187 *Jun 15, 1987May 30, 1989American Home Products CorporationSpray dried ibuprofenUS4835188 *Dec 8, 1987May 30, 1989American Home Products CorporationSpray dried ibuprofenUS4837255 *Mar 10, 1987Jun 6, 1989Ciba-Geigy CorporationPalatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resinUS4859472 *Dec 17, 1987Aug 22, 1989Boehringer Mannheim GmbhMixture with filler and lubricantUS4865851 *May 13, 1988Sep 12, 1989Glaxo Group LimitedPharmaceutical composition comprising cefuroxime axetilUS4880830 *Feb 9, 1987Nov 14, 1989Ethical Pharmaceuticals LimitedSlow release formulationUS4882152 *Oct 14, 1988Nov 21, 1989Yang Robert KConfectionery delivery system for laxatives, vitamins and antacidsUS4882167 *Nov 24, 1987Nov 21, 1989Jang Choong GookMatrix of hydrophobic carbohydrate polymer, digestive difficultly soluble wax, fatty acid or neutral lipidUS4894233 *Jul 26, 1988Jan 16, 1990Sharma Shri CNovel drug delivery system for decongestantsUS4916161 *Oct 25, 1988Apr 10, 1990Bristol-Myers SquibbTaste-masking pharmaceutical agentsGB2081092A * Title not available* Cited by examinerNon-Patent CitationsReference1Brochure entitled "Ac-Di-Sol" Croscarmellose Sodium, NF (Accelerates DisSolution), FMC Corporation 1988.2 *Brochure entitled Ac Di Sol Croscarmellose Sodium, NF (Accelerates DisSolution), FMC Corporation 1988.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5635200 *Oct 14, 1993Jun 3, 1997Glaxo Group LimitedHaving polymeric or cellulosic binder and lipid coatingUS5637313 *Dec 16, 1994Jun 10, 1997Watson Laboratories, Inc.Matrix of starch hydrolysate and mixture of a water soluble and water insoluble bulking agentUS5807577 *Nov 22, 1995Sep 15, 1998Lab Pharmaceutical Research International Inc.Fast-melt tablet and method of making sameUS5807578 *Nov 19, 1996Sep 15, 1998Lab Pharmaceutical Research International Inc.Fast-melt tablet and method of making sameUS5891476 *Dec 22, 1997Apr 6, 1999Reo; Joe P.Drug core with wax coatingUS6242019Jul 30, 1998Jun 5, 2001Warner-Lambert CompanyTaste modified hard confectionery compositions containing functional ingredientsUS6258381Feb 11, 2000Jul 10, 2001Mcneil-Ppc, Inc.Tablet and process for making the sameUS6277409 *Feb 11, 2000Aug 21, 2001Mcneil-Ppc, Inc.Molten composition comprising at least 50 weight percent of a thermoplastic material having a melting point of less than about 120 degrees c. is applied to the tablet, and solidifiedUS6375982Jul 5, 2000Apr 23, 2002Capricorn Pharma, Inc.Rapid-melt semi-solid compositions, methods of making same and method of using sameUS6406717Jul 5, 2001Jun 18, 2002Capricorn Pharma, Inc.Rapid-melt semi-solid compositions, methods of making same and methods of using sameUS6455053 *Oct 7, 1998Sep 24, 2002Ssp Co., Ltd.Quickly soluble solid preparationsUS6455068Dec 23, 1996Sep 24, 2002Onesta Nutrition, Inc.Chewable dietary fiber tablet or wager comprising, as a source of dietary fiber, a water-soluble, on-gelling inulin having a degree of polymerization of between 2 to 20, wherein the inulin is present in an amount of at least 50% by weight ofUS6982093Jul 16, 2002Jan 3, 2006Onesta Nutrition, IncorporatedDietary fiber delivery systemUS7067150Mar 25, 2003Jun 27, 2006Scepter Holdings, Inc.Digestion matrix containing carbohydrates, sugar or sugar alcohol, hydrocolloids, alcohols and water; uniform dispersionUS7229641Aug 1, 2002Jun 12, 2007Capricorn Pharma, Inc.For the delivery of prophylactic and therapeutic active materials to a mammal; formed by molding or compression, with an additional heating step being preferred.US7387803Jan 28, 2005Jun 17, 2008Cns, Inc.Dietary fiber delivery systemUS7452553Aug 19, 2004Nov 18, 2008Cns, Inc.Dietary fiber delivery systemUS7521072Aug 19, 2004Apr 21, 2009Cns, Inc.Tablet form which is palatable; soluble, which do not significantly increase in viscosity or gel when exposed to water or other liquids, yet possess the desirable organoleptic characteristicsUS7531192Apr 21, 2005May 12, 20092120812 Ontario Inc.prevents solvent glycerol separating from oral gel drug components by mixing with a blend comprising carbohydrates, hydrocolloids, sugars, sugar alcohols or sugar syrups; injection molding a gel drug forms of nutritional supplymentUS7648720Aug 29, 2008Jan 19, 2010Cns, Inc.Dietary fiber delivery systemUS7695735Mar 6, 2006Apr 13, 2010Ethypharmeffervescent free; disintegration agent such as croscarmellose, crospovidone; compressible polyol such as mannitol, xylitol; lubricant such as magnesium stearate, sodium stearyl fumarate, stearic acid, micronized polyoxyethylene glycol; sweeteners, flavorings, colors; bioavailabilityUS7767248Feb 2, 2007Aug 3, 2010Overly Iii Harry JSoft chew confectionary with high fiber and sugar content and method for making sameUS7811604Nov 14, 2006Oct 12, 2010Barr Laboratories, Inc.disintegrant such as crospovidone, croscarmellose sodium, sodium starch glycolate; free of acids, water-soluble polymers, taste-masking polymers, and coatings; formed by dry compression; for treatment of schizophreniaUS7955632Nov 14, 2007Jun 7, 2011Bayer B.V.Edible soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin; consistent weight and texture; no heat or water required during manufacture; stability; drug deliveryUS8029823Sep 15, 2008Oct 4, 2011Cosmo Technologies LimitedControlled release and taste masking oral pharmaceutical compositionUS8092826Feb 16, 2001Jan 10, 2012Kraft Foods Global Brands LlcPartially hydrogenated vegetable oils or saturated fats suppress unpleasant mouthfeel of botanicals such as Echinacea in a confectionary base, such as in nutraceuticalsUS8114455May 25, 2011Feb 14, 2012Bayer B.V.Process for manufacturing chewable dosage forms for drug delivery and products thereofUS8173161Feb 12, 2009May 8, 2012Mcneil-Ppc, Inc.Method of administering a pharmaceutical active ingredientUS8293265Jul 20, 2009Oct 23, 2012Bayer B.V.Process for manufacturing chewable dosage forms for drug delivery and products thereofUS8293273May 2, 2012Oct 23, 2012Cosmo Technologies LimitedControlled release and taste masking oral pharmaceutical compositionUS8313768Sep 22, 2010Nov 20, 2012Mcneil-Ppc, Inc.Manufacture of tablet having immediate release region and sustained release regionUS8343533Sep 22, 2010Jan 1, 2013Mcneil-Ppc, Inc.Manufacture of lozenge product with radiofrequencyUS8431154Jan 18, 2011Apr 30, 2013Takeda GmbhOral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipientUS8512787Feb 14, 2012Aug 20, 2013Bayer B.V.Process for manufacturing chewable dosage forms for drug delivery and products thereofUS8536206Jul 12, 2012Sep 17, 2013Takeda GmbhProcess for the preparation of roflumilastUS8604064Apr 10, 2013Dec 10, 2013Takeda GmbhProcess for the preparation of roflumilastUS8618142Apr 10, 2013Dec 31, 2013Takeda GmbhProcess for the preparation of roflumilastUS8663694Mar 14, 2006Mar 4, 2014Takeda GmbhTaste masked dosage form containing roflumilastUS8784781Sep 22, 2010Jul 22, 2014Mcneil-Ppc, Inc.Manufacture of chewing gum product with radiofrequencyUS8784888Sep 14, 2012Jul 22, 2014Cosmo Technologies LimitedControlled release and taste masking oral pharmaceutical compositionUS8802141May 20, 2003Aug 12, 2014John KohnkeAgent delivery systemUS8807979Sep 22, 2010Aug 19, 2014Mcneil-Ppc, Inc.Machine for the manufacture of dosage forms utilizing radiofrequency energyUSRE43799May 22, 2012Nov 13, 2012Cosmo Technologies LimitedControlled release and taste masking oral pharmaceutical compositionEP1094788A1 *Jul 8, 1999May 2, 2001Fmc CorporationCroscarmellose taste maskingWO1999033445A1 *Dec 29, 1997Jul 8, 1999Luhadiya Ashok PremchandTablet compositionWO2000027357A1 *Nov 3, 1999May 18, 2000Prographarm LabImproved fast disintegrating tabletWO2003055464A1 *Dec 27, 2002Jul 10, 2003Besins Int BelgiqueMicronized pharmaceutical or nutraceutical powder with immediate releaseWO2003097013A1 *May 16, 2002Nov 27, 2003Rodriquez Julio CesarMono-coating for powdered pharmaceuticals* Cited by examinerClassifications U.S. Classification424/441, 424/484International ClassificationA61K9/00, A61K9/16, A61K47/44, A61K9/20Cooperative ClassificationA61K9/1617, A61K9/0056, A61K9/1623European ClassificationA61K9/16H4, A61K9/00M18B, A61K9/16H4BLegal EventsDateCodeEventDescriptionJun 27, 2005FPAYFee paymentYear of fee payment: 12Jan 9, 2002REMIMaintenance fee reminder mailedNov 14, 2001FPAYFee paymentYear of fee payment: 8Nov 21, 1997FPAYFee paymentYear of fee payment: 4Oct 21, 1996ASAssignmentOwner name: LDS TECHNOLOGIES, INC., PENNSYLVANIAFree format text: FORM UCC-3-STATEMENT OF CONTINUATION, PARTIAL RELASE, ASSIGNMENTS, ETC.;ASSIGNOR:IBAH, INC.;REEL/FRAME:008478/0401Effective date: 19960617Owner name: MCNEIL-PPC, INC., NEW JERSEYFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LDS TECHNOLOGIES, INC.;REEL/FRAME:008186/0367Effective date: 19960819Jun 17, 1996ASAssignmentOwner name: LDS TECHNOLOGIES, INC., PENNSYLVANIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IBAH, INC.;REEL/FRAME:008000/0930Effective date: 19960612May 23, 1995CCCertificate of correctionJan 6, 1995ASAssignmentOwner name: IBAH, INC., PENNSYLVANIAFree format text: MERGER;ASSIGNOR:AFFINITY BIOTECH, INC.;REEL/FRAME:007275/0246Effective date: 19940427Jan 24, 1994ASAssignmentOwner name: AFFINITY BIOTECH, INC., PENNSYLVANIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GEYER, ROBERT P.;TULIANI, VINOD V.;REEL/FRAME:006833/0031Effective date: 19940113RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google